Update on pulmonary hypertension

Authors

Abstract

In the cardiology practice in our country, patients with clinical suspicion of pulmonary hypertension are frequently referred, most of them for diagnostic confirmation, definition of causes and therapeutic approach. The criterion to define it is a mean pulmonary artery pressure greater than 25 mmHg. The disease can present in different clinical processes, which are classified into five groups. In this article is presented a review of the bibliography and the most recent publications on this subject.

Downloads

Download data is not yet available.

References

1. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. DOI: https://doi.org/10.1093/eurheartj/ehv317

2. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J [Internet]. 2019 [citado 10 Ene 2021];53(1):1801913. Disponible en: https://doi.org/10.1183/13993003.01913-2018

3. Barber? JA, Román A, Gómez-Sánchez MA, Blanco I, Otero R, López-Reyes R, et al. Diagnóstico y tratamiento de la hipertensión pulmonar (Normativa SEPAR) [Internet]. Barcelona: Editorial Respira [citado 10 Ene 2021]; 2017. Disponible en: https://www.sogapar.info/wp-content/uploads/2016/12/7-Normativa-SEPAR-hipertension-pulmonar.pdf

4. Portillo K, Santos S, Madrigal I, Blanco I, Pare C, Borderias L, et al. Study of the BMPR2 gene in patients with pulmonary arterial hypertension. Arch Bronconeumol. 2010;46(3):129-34. DOI: https://doi.org/10.1016/j.arbres.2009.11.005

5. Pousada G, Baloira A, Vilariño C, Cifrian JM, Valverde D. Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension. PLoS One [Internet]. 2014 [citado 12 Ene 2021];9(6):e100261. Disponible en: https://doi.org/10.1371/journal.pone.0100261

6. Montani D, Lau EM, Dorfmüller P, Girerd B, Jaïs X, Savale L, et al. Pulmonary veno-occlusive disease. Eur Respir J. 2016;47(5):1518-34. DOI: https://doi.org/10.1183/13993003.00026-2016

7. Tenorio J, Navas P, Barrios E, Fernández L, Nevado J, Quezada CA, et al. A founder EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies. Clin Genet. 2015;88(6):579-83. DOI: https://doi.org/10.1111/cge.12549

8. Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;39(3):589-96. DOI: https://doi.org/10.1183/09031936.00092311

9. Fang JC, DeMarco T, Givertz MM, Borlaug BA, Lewis GD, Rame JE, et al. World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult - A summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2012;31(9):913-33. DOI: https://doi.org/10.1016/j.healun.2012.06.002

10. Pellegrini P, Rossi A, Pasotti M, Raineri C, Cicoira M, Bonapace S, et al. Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure. Chest. 2014;145(5):1064-70. DOI: https://doi.org/10.1378/chest.13-1510

11. Gómez-López EA. Hipertensión pulmonar asociada a enfermedad cardiaca izquierda. Enfoque diagnóstico y terapéutico. Rev Colomb Cardiol. 2017;24(Suppl 1):55-64. DOI: http://dx.doi.org/10.1016/j.rccar.2017.08.009

12. Barnett CF, Selby VM. Overview of WHO Group 2 pulmonary hypertension due to left heart disease. Advances in Pulmonary Hypertension. 2015;14(2):70-8. DOI: https://doi.org/10.21693/1933-088X-14.2.70

13. Seeger W, Adir Y, Barber? JA, Champion H, Coghlan JG, Cottin V, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25 Suppl):D109-16. DOI: https://doi.org/10.1016/j.jacc.2013.10.036

14. Barber? JA, Blanco I. Management of Pulmonary Hypertension in Patients with Chronic Lung Disease. Curr Hypertens Rep. 2015;17(8):62. DOI: https://doi.org/10.1007/s11906-015-0574-9

15. López Guide MJ, Pérez de la Sota E, Forteza Gil A, Centeno Rodríguez J, Eixeres A, Velázquez MT, et al. Pulmonary thromboendarterectomy in 106 patients with chronic thromboembolic pulmonary hypertension. Arch Bronconeumol. 2015;51(10):502-8. DOI: http://dx.doi.org/10.1016/j.arbres.2014.11.012

16. Coronel ML, Chamorro N, Blanco I, Amado V, Del Pozo R, Pomar JL, et al. Medical and surgical management for chronic thromboembolic pulmonary hypertension: a single center experience. Arch Bronconeumol. 2014;50(12):521-7. DOI: https://doi.org/10.1016/j.arbres.2014.04.011

17. Escribano-Subías P, Del Pozo R, Román-Broto A, Domingo Morera JA, Lara-Padrón A, Elías Hernández T, et al. Management and outcomes in chronic thromboembolic pulmonary hypertension: From expert centers to a nationwide perspective. Int J Cardiol. 2016;203:938-44. DOI: https://doi.org/10.1016/j.ijcard.2015.11.039

18. Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319-29. DOI: https://doi.org/10.1056/nejmoa1209657

19. Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2017;5(10):785-94. DOI: https://doi.org/10.1016/s2213-2600(17)30305-3

20. Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52(25):2127-34. DOI: https://doi.org/10.1016/j.jacc.2008.08.059

21. Olsson KM, Wiedenroth CB, Kamp JC, Breithecker A, Fuge J, Krombach GA, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J [Internet]. 2017 [citado 15 Ene 2021];49(6):1602409. Disponible en: https://doi.org/10.1183/13993003.02409-2016

22. Velázquez Martín M, Albarrán González-Trevilla A, Alonso Charterina S, García Tejada J, Cortina Romero JM, Escribano Subías P. Angioplastia pulmonar con balón en la hipertensión pulmonar tromboembólica crónica no operable. Experiencia inicial en España en una serie de 7 pacientes. Rev Esp Cardiol. 2015;68(6):535-7. DOI: https://doi.org/10.1016/j.rec.2015.02.004

23. Phan K, Jo HE, Xu J, Lau EM. Medical Therapy Versus Balloon Angioplasty for CTEPH: A Systematic Review and Meta-Analysis. Heart Lung Circ. 2018;27(1):89-98. DOI: https://doi.org/10.1016/j.hlc.2017.01.016

24. Barber? JA, Escribano P, Morales P, Gómez MA, Oribe M, Martínez A, et al. Estándares asistenciales en hipertensión pulmonar: Documento de consenso elaborado por la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y la Sociedad Española de Cardiología (SEC). Arch Bronconeumol. 2008;44(2):87-99. DOI: https://doi.org/10.1157/13115748

25. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76-81. DOI: https://doi.org/10.1056/nejm199207093270203

26. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-22. DOI: https://doi.org/10.1016/j.jacc.2010.01.027

27. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(26):2522-33. DOI: https://doi.org/10.1056/nejmoa1503184

28. Sandoval J, Gaspar J, Peña H, Santos LE, Córdova J, del Valle K, et al. Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. Eur Respir J. 2011;38(6):1343-8. DOI: https://doi.org/10.1183/09031936.00072210

29. Galiè N, Barber? JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(9):834-44. DOI: https://doi.org/10.1056/nejmoa1413687

30. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296-301. DOI: https://doi.org/10.1056/nejm199602013340504

31. Sitbon O, Jaïs X, Savale L, Cottin V, Bergot E, Macari EA, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43(6):1691-7. DOI: https://doi.org/10.1183/09031936.00116313

32. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(1 Suppl):35S-62S. DOI: https://doi.org/10.1378/chest.126.1_suppl.35s

33. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780-8. DOI: https://doi.org/10.1016/s0735-1097(02)02012-0

34. Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galiè N, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax. 2005;60(12):1025-30. DOI: https://doi.org/10.1136/thx.2005.040618

35. Wensel R, Opitz CF, Anker SD, Winkler J, Höffken G, Kleber FX, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002;106(3):319-24. DOI: https://doi.org/10.1161/01.cir.0000022687.18568.2a

36. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation. 2001;104(4):429-35. DOI: https://doi.org/10.1161/hc2901.093198

37. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102(8):865-70. DOI: https://doi.org/10.1161/01.cir.102.8.865

38. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006;129(5):1313-21. DOI: https://doi.org/10.1378/chest.129.5.1313

39. Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol. 2002;39(7):1214-9. DOI: https://doi.org/10.1016/s0735-1097(02)01744-8

40. Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174(9):1034-41. DOI: https://doi.org/10.1164/rccm.200604-547oc

41. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25(2):244-9. DOI: https://doi.org/10.1183/09031936.05.00054804

Downloads

Published

2021-10-09

How to Cite

1.
Echarte Martínez JC, Hechavarria Pouymiró S, Alfonso Rodríguez E. Update on pulmonary hypertension. CorSalud [Internet]. 2021 Oct. 9 [cited 2025 Jun. 22];13(4):460-72. Available from: https://revcorsalud.sld.cu/index.php/cors/article/view/728

Issue

Vol. 13 No. 4 (2021)

Section

REVIEW ARTICLE

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.